COLORADO SPRINGS, Colo.,
March 11, 2014 /PRNewswire/
-- Cannabis Science, Inc., (NASDAQ OTCQB: CBIS) a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, applauds CNN's Dr. Sanjay Gupta for continuing to bring to public
attention the medical value of cannabis to patients and the
challenges that patients face in seeking cannabis-based
life-savings treatments.
Leading up to the airing of his new documentary, 'Weed 2', to be
aired this evening on CNN at 10 p.m.
EDT, Dr. Gupta published an article in which he states,
among other things, that "I am more convinced than ever that it is
irresponsible to not provide the best [medical] care we can, care
that often may involve marijuana. I am not backing down on
medical marijuana; I am doubling down."
You may read the full pre-documentary article at the following
link:
http://www.cnn.com/2014/03/05/health/gupta-medical-marijuana/index.html
"Dr. Gupta's well researched support for patient access to
medical cannabis provides a critical voice for those in need of all
effective treatment options. The majority of Americans now
shares this view. We hope and believe that such life-saving
access will continue to expand to more and more people in need,"
said Chad S. Johnson, Esq.,
Director, COO, & General Counsel of Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries:
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
SOURCE Cannabis Science, Inc.